Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other financing activities (2017 - 2024)

Fate Therapeutics' Other financing activities history spans 5 years, with the latest figure at -$558000.0 for Q2 2024.

  • For Q2 2024, Other financing activities fell 1000.0% year-over-year to -$558000.0; the TTM value through Mar 2025 reached $62000.0, down 90.3%, while the annual FY2021 figure was $133000.0, N/A changed from the prior year.
  • Other financing activities reached -$558000.0 in Q2 2024 per FATE's latest filing, down from $558000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $558000.0 in Q1 2024 to a low of -$558000.0 in Q2 2024.